Zai Lab Ltd
ZLAB37.510USD
+0.690+1.87%
Market hours （ET）Quotes delayed by 15 min
4.07BMarket Cap
LossP/E TTM
More Details of Zai Lab Ltd Company
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Company Info
Ticker SymbolZLAB
Company nameZai Lab Ltd
IPO dateSep 28, 2020
CEODr. Du (Samantha) Ying, Ph.D.
Number of employees1869
Security typeDepository Receipt
Fiscal year-endSep 28
AddressBuilding B, 899 Halei Road, Pudong
CitySHANGHAI
Stock exchangeNASDAQ Global Market Consolidated
CountryChina
Postal code201203
Phone862161632588
Websitehttps://www.zailaboratory.com/
Ticker SymbolZLAB
IPO dateSep 28, 2020
CEODr. Du (Samantha) Ying, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+12.18%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
67.34K
+55.78%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-7.83%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
21.00K
-22.34%
Dr. Du (Samantha) Ying, Ph.D.
Dr. Du (Samantha) Ying, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Mr. Michel Pericles Vounatsos
Mr. Michel Pericles Vounatsos
Independent Director
Independent Director
--
--
Dr. Richard B. Gaynor, M.D.
Dr. Richard B. Gaynor, M.D.
Independent Director
Independent Director
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Mr. Peter Karl Wirth, J.D.
Mr. Peter Karl Wirth, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+12.18%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
67.34K
+55.78%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-7.83%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
21.00K
-22.34%
Dr. Du (Samantha) Ying, Ph.D.
Dr. Du (Samantha) Ying, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
By BusinessUSD
Name
Revenue
Proportion
ZEJULA
49.53M
46.88%
VYVGART
18.11M
17.14%
NUZYRA
15.12M
14.31%
Optune
11.36M
10.76%
QINLOCK
8.51M
8.05%
Other
3.03M
2.86%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
ZEJULA
49.53M
46.88%
VYVGART
18.11M
17.14%
NUZYRA
15.12M
14.31%
Optune
11.36M
10.76%
QINLOCK
8.51M
8.05%
Other
3.03M
2.86%
Shareholding Stats
Updated: Sun, Aug 3
Updated: Sun, Aug 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
5.41%
Fidelity Management & Research Company LLC
4.21%
Janus Henderson Investors
3.43%
Wellington Management Company, LLP
3.28%
ClearBridge Investments, LLC
2.95%
Other
80.71%
Shareholders
Shareholders
Proportion
Capital World Investors
5.41%
Fidelity Management & Research Company LLC
4.21%
Janus Henderson Investors
3.43%
Wellington Management Company, LLP
3.28%
ClearBridge Investments, LLC
2.95%
Other
80.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.70%
Investment Advisor/Hedge Fund
19.15%
Hedge Fund
5.67%
Research Firm
2.88%
Individual Investor
1.42%
Venture Capital
1.39%
Pension Fund
0.67%
Private Equity
0.32%
Sovereign Wealth Fund
0.18%
Other
47.63%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
393
64.25M
57.85%
-6.53M
2025Q1
453
59.51M
53.68%
-14.18M
2024Q4
446
60.80M
55.47%
-4.29M
2024Q3
439
51.45M
51.99%
-10.14M
2024Q2
454
47.04M
47.66%
-14.67M
2024Q1
465
46.22M
46.47%
-13.77M
2023Q4
497
46.31M
46.92%
-16.57M
2023Q3
537
44.27M
45.68%
-20.42M
2023Q2
568
47.21M
48.74%
-23.76M
2023Q1
572
60.29M
61.61%
-11.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
6.01M
5.41%
-425.00K
-6.61%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.68M
4.21%
+945.91K
+25.33%
Mar 31, 2025
Janus Henderson Investors
3.81M
3.43%
-2.75M
-41.94%
Mar 31, 2025
Wellington Management Company, LLP
3.65M
3.28%
-3.01M
-45.22%
Mar 31, 2025
ClearBridge Investments, LLC
3.28M
2.95%
+1.42M
+76.05%
Mar 31, 2025
RTW Investments L.P.
3.14M
2.82%
+627.56K
+25.01%
Mar 31, 2025
Principal Global Investors (Equity)
2.88M
2.6%
+1.12M
+63.64%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.45M
2.2%
-532.32K
-17.86%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.27M
2.04%
-85.81K
-3.65%
Mar 31, 2025
Baron Capital Management, Inc.
1.83M
1.65%
-79.59K
-4.17%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Tema Oncology ETF
3.06%
ALPS Medical Breakthroughs ETF
2.67%
Virtus LifeSci Biotech Products ETF
1.57%
Invesco Golden Dragon China ETF
1.14%
Innovator IBD 50 Fund ETF
0.94%
National Security Emerging Markets Index ETF
0.43%
iShares Biotechnology ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.23%
Invesco Nasdaq Biotechnology ETF
0.23%
Capital Group New Geography Equity ETF
0.21%
View more
Tema Oncology ETF
Proportion3.06%
ALPS Medical Breakthroughs ETF
Proportion2.67%
Virtus LifeSci Biotech Products ETF
Proportion1.57%
Invesco Golden Dragon China ETF
Proportion1.14%
Innovator IBD 50 Fund ETF
Proportion0.94%
National Security Emerging Markets Index ETF
Proportion0.43%
iShares Biotechnology ETF
Proportion0.25%
ProShares Ultra Nasdaq Biotechnology
Proportion0.23%
Invesco Nasdaq Biotechnology ETF
Proportion0.23%
Capital Group New Geography Equity ETF
Proportion0.21%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
